secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K/A
Filed at:   2026-04-24T23:59:59+00:00
Accession:  0001645113-26-000038
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NovoCure discloses CEO Frank Leonard's pay: CHF 750K base, 90% target bonus, enhanced severance
--------------------------------------------------------------------------------

- Base salary of CHF 750,000 and target annual bonus of 90% of base (CHF 675,000).
- Eligible for equity awards under 2024 Omnibus Incentive Plan; relocation and tax indemnification provided.
- Severance on qualifying termination: 100% base salary; within 12 months post-change-in-control: 200% base + 200% target bonus plus full equity vesting.
- Non-compete covenant for 12 months after termination; perpetual non-disparagement.
- Amendment filed to supplement Dec. 1, 2025 8-K; compensation details now finalized.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000038/0001645113-26-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000038/nvcr-20251124.htm
  HTML page:      https://secwatch.observer/filing/0001645113-26-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer